23d
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the ...
Scheduled for August 2025 completion, the initial $2-billion phase included construction of a 1-million-sq-ft complex with two drug substance manufacturing buildings, each containing four 20,000-liter ...
The "Fill Finish Manufacturing Market - A Global and Regional Analysis: Focus on Product, End Users, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.
Leveraging Northway Biotech's 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...
Hosted on MSN
A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is ...
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is a proposed new multi-billion dollar drug substance ...
A straZeneca plans to invest $50 billion in its medicine manufacturing and R&D operations across the United States by 2030. The investment is expected to create tens of thousands of new, highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback